Study guide
32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules
Philippine Physician Licensure Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: PLE Structure, Eligibility & Study Strategy
1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan
2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle
2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction
3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems
3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments
4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems
4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation
5 Chapter 5: Physiology IV: Neurophysiology & Special Senses
5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses
6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death
6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death
7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning
7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws
8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics
8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics
9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics
9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock
10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection
10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology
11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology
11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura
12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology
12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors
13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry
13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism
14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry
14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure
15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back
15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes
16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin
16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands
17 Chapter 17: Anatomy III: Head, Neck & Histology
17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology
18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections
18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis
19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections
19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning
20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections
20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases
21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections
21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis
22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding
22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage
23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems
23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception
24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception
24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria
25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues
25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents
26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections
26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections
27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders
27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning
28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders
28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child
29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider
29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036
30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine
30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine
31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer
31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health
32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics
32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections
33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics
33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy
34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics
34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis
35 Chapter 35: Surgery I: Basic Surgical Principles
35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety
36 Chapter 36: Surgery II: Abdomen, Breast & Hernia
36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma
37 Chapter 37: Surgery III: Surgical Specialties
37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)
38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine
38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome
39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine
39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS
40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry
40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)
32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules
Key Takeaways Explain This Topic AI
The loading dose depends on the volume of distribution (target concentration times Vd divided by F); the maintenance dose depends on clearance; steady state is reached after 4 to 5 half-lives.
Phenytoin, ethanol and high-dose aspirin follow zero-order (saturable) elimination, so small dose increases can cause large rises in level.
Rifampicin, carbamazepine, phenytoin, phenobarbital and St John's wort induce CYP450; macrolides (not azithromycin), azoles, ritonavir, cimetidine and grapefruit juice inhibit it.
A competitive antagonist shifts the dose-response curve to the right without lowering the maximum effect; a non-competitive antagonist lowers the maximum effect.
Organophosphate poisoning causes muscarinic (SLUDGE, bronchorrhea, bradycardia) and nicotinic (fasciculations, paralysis) toxicity, treated with atropine titrated to dry secretions plus pralidoxime.
Last updated: October 2026
Why this area matters
The Pharmacology and Therapeutics TOS lists seven organ-system areas:
Area Weight
Cardiovascular (arrest, heart block, arrhythmia, ischemia and ACS, hypertension and emergencies, shock, heart failure, pericarditis, dyslipidemia, CV infections) 16%
Nervous system (headache, seizures, vertigo, stroke, encephalopathy, psychiatric disorders, dementia, ADHD, Parkinson disease, intracranial hematoma, CNS infections) 15%
Respiratory (cough and colds, allergic rhinitis, asthma, COPD, TB, pneumonia, bronchitis, lung cancer) 14%
Genitourinary (UTI, stones, nephrotic and nephritic disease, prostate disease, STIs, genital ulcers and warts, PID, renal and prostate cancer) 16%
Digestive (portal hypertension and GI bleeding, ulcer disease, GERD, constipation and diarrhea, biliary and pancreatic disease, GI infections, hepatitis, GI cancer) 12%
Endocrine (pituitary, diabetes, thyroid, calcium and parathyroid, adrenal) 15%
Cutaneous and musculoskeletal (cellulitis, drug-induced skin reactions, pain, osteoporosis, arthritis, gout, SLE, psoriasis) 12%
For every drug, be ready to:
- explain its mechanism and link it to the disease;
- choose it rationally in a clinical scenario;
- predict adverse effects at usual and toxic doses;
- recognize interactions with drugs, food and laboratory tests;
plan monitoring.
Quantitative Pharmacokinetics: Volume of Distribution, Clearance & Dosing Regimens
Pharmacokinetics describes what the human body does to an administered xenobiotic, fundamentally broken down into Absorption, Distribution, Metabolism, and Elimination (ADME).
Volume of Distribution ( V d V_d V d )
The apparent Volume of Distribution ( V d V_d V d ) is a proportionality constant that relates the total amount of drug in the body to the plasma drug concentration ( C 0 C_0 C 0 ) measured immediately after intravenous distribution:
V d = Total amount of drug in body C 0 = Dose C 0 V_d = \frac{\text{Total amount of drug in body}}{C_0} = \frac{\text{Dose}}{C_0} V d = C 0 Total amount of drug in body = C 0 Dose
V d V_d V d does not represent a real anatomical volume; rather, it reflects the relative affinity of a drug for vascular versus extravascular tissue compartments:
Low V d V_d V d ( 4 – 8 L 4\text{--}8\text{ L} 4 – 8 L , approximately 0.05 – 0.1 L/kg 0.05\text{--}0.1\text{ L/kg} 0.05 – 0.1 L/kg ) : Confined largely to the intravascular plasma volume ( 3 – 4 L 3\text{--}4\text{ L} 3 – 4 L ). These drugs possess high molecular weights, strong negative charges, or extensive binding to circulating plasma albumin (e.g., Warfarin, Heparin). Because the drug remains in the vascular space, C 0 C_0 C 0 is high and calculated V d V_d V d is low.
Intermediate V d V_d V d ( 12 – 16 L 12\text{--}16\text{ L} 12 – 16 L , approximately 0.2 L/kg 0.2\text{ L/kg} 0.2 L/kg ) : Distributed throughout the extracellular fluid (ECF = plasma + + + interstitial space). These are small, hydrophilic, polar molecules that cannot readily penetrate lipid cell membranes (e.g., Aminoglycosides, Beta-lactams).
High V d V_d V d ( > 40 L > 40\text{ L} > 40 L , up to thousands of liters in lipophilic drugs) : Distributed throughout total body water ( 42 L 42\text{ L} 42 L ) and extensively sequestered within extravascular tissues (adipose tissue, liver, bone, skeletal muscle). Because plasma concentrations ( C 0 C_0 C 0 ) are extremely low, calculated V d V_d V d far exceeds total anatomical body volume (e.g., Digoxin V d ≈ 500 L V_d \approx 500\text{ L} V d ≈ 500 L , Chloroquine V d > 10 , 000 L V_d > 10,000\text{ L} V d > 10 , 000 L , Tricyclic Antidepressants). Drugs with very high V d V_d V d cannot be cleared effectively by emergency hemodialysis during acute poisoning.
Clearance ( C L CL C L ) and Elimination Half-Life ( t 1 / 2 t_{1/2} t 1/2 )
Clearance ( C L CL C L ) is the volume of plasma completely cleared of drug per unit time (expressed in mL/min \text{mL/min} mL/min or L/hr \text{L/hr} L/hr ):
C L = Rate of elimination C p = k e × V d CL = \frac{\text{Rate of elimination}}{C_p} = k_e \times V_d C L = C p Rate of elimination = k e × V d
Where k e k_e k e is the first-order elimination rate constant (the fraction of drug eliminated per unit time). Clearance is additive across eliminating organs: C L total = C L renal + C L hepatic + C L biliary/pulmonary CL_{\text{total}} = CL_{\text{renal}} + CL_{\text{hepatic}} + CL_{\text{biliary/pulmonary}} C L total = C L renal + C L hepatic + C L biliary/pulmonary .
The Elimination Half-Life ( t 1 / 2 t_{1/2} t 1/2 ) is the time required for the plasma concentration to decrease by 50% under first-order conditions. It is governed entirely by V d V_d V d and C L CL C L :
t 1 / 2 = ln ( 2 ) k e = 0.693 × V d C L t_{1/2} = \frac{\ln(2)}{k_e} = \frac{0.693 \times V_d}{CL} t 1/2 = k e l n ( 2 ) = C L 0.693 × V d
Severe chronic kidney disease or cirrhosis reduces clearance ( C L CL C L ), prolonging t 1 / 2 t_{1/2} t 1/2 .
Volume expansion (massive ascites, severe generalized anasarca, aggressive fluid resuscitation) increases V d V_d V d of hydrophilic drugs, which also prolongs t 1 / 2 t_{1/2} t 1/2 and lowers peak plasma levels.
Loading Dose ( L D LD L D ) vs. Maintenance Dose ( M D MD M D )
When treating acute, life-threatening conditions (severe sepsis, status epilepticus, acute pulmonary edema), clinicians cannot wait for multiple half-lives to elapse before achieving therapeutic efficacy. A Loading Dose ( L D LD L D ) is administered to rapidly achieve the target plasma concentration ( C target C_{\text{target}} C target ):
L D = C target × V d F LD = \frac{C_{\text{target}} \times V_d}{F} L D = F C target × V d
Where F F F represents bioavailability (the fraction of unchanged drug reaching systemic circulation; for intravenous administration, F = 1.0 F = 1.0 F = 1.0 ). Loading dose depends exclusively on Volume of Distribution ( V d V_d V d ) and is completely independent of clearance or organ function.
Once therapeutic concentrations are established, a Maintenance Dose ( M D MD M D ) is administered at scheduled dosing intervals ( τ \tau τ ) to replace the drug lost through ongoing elimination:
M D = C s s × C L × τ F MD = \frac{C_{ss} \times CL \times \tau}{F} M D = F C ss × C L × τ
Where C s s C_{ss} C ss is the desired steady-state plasma concentration. Maintenance dose depends directly on Clearance ( C L CL C L ) ; in renal or hepatic failure, the maintenance dose must be adjusted downward by reducing the dose or extending the dosing interval ( τ \tau τ ).
Steady-State Kinetics
Under continuous infusion or regular repeated dosing, a drug reaches Steady State ( C s s C_{ss} C ss ) when the rate of drug input equals the rate of drug elimination. The time required to attain steady state depends solely on the drug's elimination half-life ( t 1 / 2 t_{1/2} t 1/2 ):
- 1 t 1 / 2 = 50.0 % 1\ t_{1/2} = 50.0\% 1 t 1/2 = 50.0% of steady state
- 2 t 1 / 2 = 75.0 % 2\ t_{1/2} = 75.0\% 2 t 1/2 = 75.0% of steady state
- 3 t 1 / 2 = 87.5 % 3\ t_{1/2} = 87.5\% 3 t 1/2 = 87.5% of steady state
- 3.3 t 1 / 2 = 90.0 % 3.3\ t_{1/2} = 90.0\% 3.3 t 1/2 = 90.0% of steady state
- 4 t 1 / 2 = 93.75 % 4\ t_{1/2} = 93.75\% 4 t 1/2 = 93.75% of steady state
- 5 t 1 / 2 = 96.88 % 5\ t_{1/2} = 96.88\% 5 t 1/2 = 96.88% of steady state
In clinical pharmacology, steady state is functionally achieved after 4 to 5 half-lives . Increasing the infusion rate or dose size increases the eventual steady-state concentration ( C s s C_{ss} C ss ), but does not shorten the time required to reach steady state.
Elimination Kinetics: First-Order vs. Zero-Order
Kinetic Property First-Order Elimination Zero-Order Elimination
Rate of Elimination Proportional to plasma drug concentration ( − d C d t = k e ⋅ C -\frac{dC}{dt} = k_e \cdot C − d t d C = k e ⋅ C ) Constant, independent of drug concentration ( − d C d t = k 0 -\frac{dC}{dt} = k_0 − d t d C = k 0 )
Fraction Eliminated per Unit Time Constant fraction (e.g., 50% cleared per half-life) Variable fraction (fraction cleared decreases as concentration rises)
Amount Eliminated per Unit Time Variable amount (decreases as plasma level falls) Constant amount (e.g., fixed 10 mg/hr 10\text{ mg/hr} 10 mg/hr cleared)
Elimination Half-Life ( t 1 / 2 t_{1/2} t 1/2 ) Constant ( t 1 / 2 = 0.693 ⋅ V d / C L t_{1/2} = 0.693 \cdot V_d / CL t 1/2 = 0.693 ⋅ V d / C L ) Variable (increases proportionally with dose)
Clearance ( C L CL C L ) Constant over therapeutic dose ranges Decreases as dose increases (capacity-limited)
Plasma Concentration vs. Time Plot Exponential decay on linear plot; Straight line on semi-log plot Straight downward line on linear plot; Concave curve on semi-log plot
Classic Clinical Examples Vast majority ( > 95 % > 95\% > 95% ) of clinical drugs PEA : P henytoin, E thanol, A spirin (at toxic or high anti-inflammatory doses)
PLE High-Yield Point : In zero-order kinetics, metabolic elimination mechanisms (hepatic conjugating enzymes or active renal tubular transporters) become completely saturated at therapeutic or supratherapeutic concentrations. Consequently, a small incremental dose increase can lead to disproportionate, exponential surges in plasma drug concentration, precipitating catastrophic toxicity.
Hepatic Biotransformation: Phase I vs. Phase II Metabolism & CYP450 Interactions
Most pharmacological agents are lipophilic molecules that would undergo continuous passive reabsorption across renal tubular epithelial membranes if excreted unchanged. The liver converts lipophilic xenobiotics into polar, water-soluble metabolites for excretion in urine or bile.
Phase I vs. Phase II Reactions
Phase I Reactions (Functionalization) :
Includes Oxidation, Reduction, and Hydrolysis .
Introduces or unmasks a polar functional group (such as − OH -\text{OH} − OH , − NH 2 -\text{NH}_2 − NH 2 , or − SH -\text{SH} − SH ).
Predominantly catalyzed by the microsomal Cytochrome P450 (CYP450) monooxygenase superfamily located in the smooth endoplasmic reticulum.
Phase I metabolites are often chemically active, sometimes possessing enhanced pharmacological activity (e.g., diazepam to oxazepam) or toxic potential.
Geriatric Vulnerability : Phase I hepatic enzymatic capacity declines significantly with advanced age. Elderly patients clear Phase I drugs more slowly.
Phase II Reactions (Conjugation) :
Includes Glucuronidation, Acetylation, Sulfation, Methylation, and Glutathione conjugation .
Covalently couples the polar functional group to an endogenous hydrophilic substrate (e.g., UDP-glucuronic acid, acetyl-CoA, sulfate, glutathione).
Yields biologically inactive, highly polar, water-soluble conjugates that are rapidly cleared by renal glomerular filtration and active tubular secretion.
Preserved in Geriatrics : Phase II conjugation mechanisms are well preserved in elderly individuals. Clinical mnemonic: Geriatric patients have More GAS ( G lucuronidation, A cetylation, S ulfation). When prescribing benzodiazepines to geriatric patients or individuals with cirrhosis, agents that undergo direct Phase II metabolism without active Phase I intermediates are preferred: LOT ( L orazepam, O xazepam, T emazepam).
Pharmacogenetic Acetylation: Slow vs. Fast Acetylators
Phase II acetylation is catalyzed by hepatic N-acetyltransferase-2 (NAT2) . Genetically determined slow acetylators possess deficient NAT2 activity (autosomal recessive trait, found in roughly 50% of Caucasian and African populations, but < 15 % < 15\% < 15% of Asian populations). Slow acetylators accumulate parent drugs, predisposing them to dose-dependent toxicities and Drug-Induced Lupus Erythematosus (DILE) . Classic offending agents include:
- Isoniazid (severe peripheral neuropathy due to pyridoxine deficiency, hepatotoxicity)
- Hydralazine (DILE with positive anti-histone antibodies)
- Procainamide (DILE with highest incidence)
- Cytochrome P450 Modulators
Co-administration of drugs that induce or inhibit CYP450 enzymes represents a primary cause of adverse drug reactions and therapeutic failures.
CYP450 Inducers (Accelerate Metabolism, Reduce Drug Efficacy) CYP450 Inhibitors (Block Metabolism, Precipitate Drug Toxicity)
- Rifampin (most potent inducer across CYP3A4, 2C9, 2C19) Cimetidine (potent H 2 H_2 H 2 blocker inhibitor)
- Phenytoin & Fosphenytoin Ciprofloxacin & fluoroquinolones (inhibit CYP1A2)
- Carbamazepine (auto-induces its own metabolism) Azole antifungals (Ketoconazole, Fluconazole, Voriconazole)
- Phenobarbital & Barbiturates Macrolide antibiotics (Erythromycin, Clarithromycin; not Azithromycin)
- St. John's wort ( Hypericum perforatum , herbal antidepressant) Isoniazid (inhibits CYP2C19 and CYP3A4)
Chronic alcohol intake (induces CYP2E1) Grapefruit juice (furanocoumarins irreversibly inhibit intestinal CYP3A4)
Griseofulvin (antifungal) Protease inhibitors (Ritonavir, booster agent)
Smoking / Polycyclic aromatic hydrocarbons (induce CYP1A2) Acute alcohol intoxication / binge (competes for CYP enzymes)
Pharmacodynamics: Potency, Efficacy, Antagonism & Therapeutic Index
Pharmacodynamics analyzes what a drug does to the body, exploring biochemical receptor interactions, dose-response relationships, and signal transduction cascades.
Potency vs. Efficacy
Potency : The concentration or dose of a drug required to produce 50% of its maximal response ( E C 50 EC_{50} E C 50 or E D 50 ED_{50} E D 50 ). On a semi-logarithmic concentration-effect curve, a drug with higher potency has a curve shifted to the left (lower E C 50 EC_{50} E C 50 ). Potency is primarily determined by receptor affinity ( K d K_d K d ) and tissue receptor density.
Efficacy : The maximal response achievable by a drug ( E max E_{\max} E m a x ), reflecting intrinsic activity once bound to the receptor. On a concentration-effect curve, efficacy is measured by the vertical height of the plateau. In clinical medicine, efficacy is far more important than potency ; a drug that can completely suppress pain or control severe hypertension is clinically superior to a more potent drug that achieves only partial symptom control.
Receptor Antagonism Profiles
Competitive Antagonist :
Binds reversibly to the identical active orthosteric receptor site as the agonist.
Effect on Curve : Causes a parallel shift to the right of the agonist log concentration-response curve.
Kinetic Changes : Increases E C 50 EC_{50} E C 50 (reduces apparent potency) while leaving E max E_{\max} E m a x unchanged .
Can be completely surmounted and overcome by administering higher concentrations of the agonist.
Examples : Atropine competing with Acetylcholine; Phentolamine competing with Norepinephrine; Naloxone competing with Morphine; Flumazenil competing with benzodiazepines.
Non-Competitive Antagonist :
Binds irreversibly (covalently) to the orthosteric active site, or binds reversibly to a separate allosteric regulatory site.
Effect on Curve : Depresses the agonist concentration-response curve downward.
Kinetic Changes : Reduces E max E_{\max} E m a x (reduces efficacy); the E C 50 EC_{50} E C 50 may remain unchanged or shift slightly.
Cannot be surmounted , regardless of how much agonist is added, because available functional receptors are permanently inactivated or structurally modified.
Examples : Phenoxybenzamine covalently binding alpha-adrenergic receptors; Aspirin irreversibly acetylating cyclooxygenase.
Therapeutic Index ( T I TI T I )
The Therapeutic Index ( T I TI T I ) quantifies drug safety by comparing the median toxic dose to the median effective dose:
T I = T D 50 E D 50 ( or L D 50 E D 50 in preclinical animal lethality studies ) TI = \frac{TD_{50}}{ED_{50}} \quad \left(\text{or } \frac{LD_{50}}{ED_{50}} \text{ in preclinical animal lethality studies}\right) T I = E D 50 T D 50 ( or E D 50 L D 50 in preclinical animal lethality studies )
A high T I TI T I indicates a wide margin of safety (e.g., penicillin). A low T I TI T I indicates a narrow margin of safety requiring routine Therapeutic Drug Monitoring (TDM) . Narrow therapeutic index drugs frequently tested on the PLE include:
- Warfarin (monitor PT/INR)
- Theophylline (monitor serum levels; toxicity causes refractory seizures and fatal arrhythmias)
- Digoxin (monitor serum levels, narrow window 0.5 – 0.9 ng/mL 0.5\text{--}0.9\text{ ng/mL} 0.5 – 0.9 ng/mL )
- Lithium (monitor serum levels, target 0.6 – 1.2 mEq/L 0.6\text{--}1.2\text{ mEq/L} 0.6 – 1.2 mEq/L )
- Carbamazepine & Phenytoin (monitor serum levels)
- Aminoglycosides (monitor peak and trough concentrations)
- Autonomic Pharmacology: Cholinergic System
The autonomic nervous system (ANS) maintains visceral homeostasis through opposing cholinergic (parasympathetic) and adrenergic (sympathetic) signaling branches.
Cholinergic Receptors & Second Messengers
M 1 M_1 M 1 Receptors ( G q → Phospholipase C → I P 3 / D A G → ↑ C a 2 + G_q \to \text{Phospholipase C} \to IP_3 / DAG \to \uparrow Ca^{2+} G q → Phospholipase C → I P 3 / D A G →↑ C a 2 + ) : Expressed in central nervous system neurons and gastric parietal/enteric ganglia.
M 2 M_2 M 2 Receptors ( G i → ↓ cAMP → opens K + channels G_i \to \downarrow \text{cAMP} \to \text{opens } K^+ \text{ channels} G i →↓ cAMP → opens K + channels ) : Expressed in cardiac nodal tissue (sinoatrial node, atrioventricular node). Stimulation hyperpolarizes nodal cells, slowing heart rate ( negative chronotropy ) and decreasing AV conduction velocity ( negative dromotropy ).
M 3 M_3 M 3 Receptors ( G q → I P 3 / D A G → ↑ C a 2 + G_q \to IP_3 / DAG \to \uparrow Ca^{2+} G q → I P 3 / D A G →↑ C a 2 + ) : Expressed in exocrine glands (sweat, lacrimal, salivary, gastric glands → \to → profuse secretion), visceral smooth muscle (bronchoconstriction, detrusor contraction, bladder emptying, hypermotility/cramping), and pupillary sphincter muscle (constriction → \to → miosis and ciliary muscle spasm → \to → accommodation for near vision). On vascular endothelium, M 3 M_3 M 3 stimulation drives endothelial nitric oxide synthase (eNOS) to release Nitric Oxide (NO), stimulating guanylyl cyclase to generate cyclic GMP, causing paradoxical vasodilation .
Nicotinic Receptors ( N N N_N N N and N M N_M N M ) : Ligand-gated ion channels. N N N_N N N is found on autonomic ganglia and the adrenal medulla; N M N_M N M is located on the skeletal muscle motor end-plate. Binding of acetylcholine opens non-selective cation channels, driving massive inward N a + Na^+ N a + current and end-plate depolarization.
Cholinomimetic & Anticholinergic Agents
Direct Muscarinic Agonists :
Bethanechol : Quaternary amine resistant to AChE; activates bowel and bladder smooth muscle. Used for non-obstructive postoperative urinary retention, neurogenic ileus, and diabetic gastroparesis.
Pilocarpine : Tertiary amine (penetrates cornea); causes rapid miosis and contracts the ciliary muscle, pulling open the trabecular meshwork to drain aqueous humor in acute angle-closure glaucoma; also stimulates salivation in Sjögren syndrome.
Methacholine : Inhaled muscarinic agonist used in bronchial challenge testing for diagnosing bronchial hyperreactivity in suspected asthma.
Muscarinic Antagonists (Anticholinergics) :
Atropine : Prototypic non-selective competitive muscarinic blocker. Reverses bradycardia, dries secretions, and causes mydriasis and cycloplegia.
Scopolamine : Crosses blood-brain barrier; transdermal patch used for motion sickness prophylaxis and end-of-life terminal respiratory secretions.
Ipratropium & Tiotropium : Inhaled quaternary ammonium derivatives; block M 3 M_3 M 3 receptors in bronchial smooth muscle without systemic anticholinergic absorption; first-line bronchodilators in COPD.
Oxybutynin & Tolterodine : Antagonize M 3 M_3 M 3 receptors on detrusor muscle, reducing bladder spasms in urge incontinence and overactive bladder.
Benztropine & Trihexyphenidyl : Central anticholinergics used to restore the dopaminergic-cholinergic balance in Parkinson disease and treat acute antipsychotic-induced extrapyramidal dystonias.
Anticholinergic Toxicity Syndrome
Excessive muscarinic blockade precipitates the classic clinical toxidrome:
- "Blind as a bat" : Severe mydriasis, loss of accommodation (cycloplegia)
- "Mad as a hatter" : Delirium, toxic psychosis, hallucinations, agitation
- "Red as a beet" : Cutaneous vasodilation and flushing
- "Hot as a hare" : Hyperthermia due to complete cessation of sweating (anhidrosis)
- "Dry as a bone" : Severe xerostomia, parched mucous membranes, dry skin
- "Bowel and bladder lose their tone" : Absent bowel sounds, paralytic ileus, acute urinary retention
- "Heart runs alone" : Severe sinus tachycardia
Treatment of severe central anticholinergic toxicity is Physostigmine , a tertiary amine acetylcholinesterase inhibitor that readily crosses the blood-brain barrier to restore central and peripheral acetylcholine levels.
Acetylcholinesterase (AChE) Inhibitors & Organophosphate Toxicity
Reversible AChE Inhibitors :
Neostigmine : Quaternary amine (does not cross BBB); reverses non-depolarizing neuromuscular blockade (rocuronium) and treats myasthenia gravis and acute colonic pseudo-obstruction (Ogilvie syndrome).
Pyridostigmine : Quaternary amine; long-acting maintenance therapy for Myasthenia Gravis.
Physostigmine : Tertiary amine (penetrates CNS); antidote for anticholinergic poisoning.
Donepezil, Rivastigmine, Galantamine : Lipid-soluble central AChE inhibitors; first-line symptomatic therapy for Alzheimer disease dementia.
Edrophonium : Ultra-short-acting inhibitor historically used in the Tensilon test to differentiate myasthenic crisis (improves with drug) from cholinergic crisis (worsens with drug).
Irreversible AChE Inhibitors (Organophosphate Pesticides: Malathion, Parathion, Chlorpyrifos; Nerve Agents: Sarin, Soman) :
Covalently phosphorylate the active catalytic serine residue of acetylcholinesterase, completely blocking acetylcholine degradation.
Clinical Manifestations : Muscarinic hyperstimulation produces the classic mnemonic SLUDGE ( S alivation, L acrimation, U rination, D efecation, G astrointestinal cramping, E mesis) or DUMBBELLS ( D iarrhea, U rination, M iosis, B ronchospasm, B radycardia, E mesis, L acrimation, L ethargy, S alivation). The life-threatening "Killer Bs"— Bronchorrhea, Bronchospasm, and Bradycardia —cause acute respiratory arrest.
Nicotinic hyperstimulation produces muscle fasciculations, cramping, followed rapidly by depolarizing flaccid paralysis of the diaphragm.
Emergency Antidote Protocol :
Atropine : Competitive antagonist at muscarinic receptors. Administer immediate intravenous boluses (doubling the dose every 3 to 5 minutes) titrated aggressively until tracheobronchial secretions dry and bronchospasm clears. Atropine reverses muscarinic pulmonary collapse, but has zero effect on nicotinic neuromuscular paralysis .
Pralidoxime (2-PAM) : A nucleophilic oxime that chemically cleaves the covalent organophosphate bond from acetylcholinesterase, regenerating active functional enzyme at both muscarinic and nicotinic synapses. Must be administered promptly before chemical "aging" (dealkylation of the organophosphate-enzyme complex) permanently locks the enzyme in an irreversible inactivated state.
- Autonomic Pharmacology: Adrenergic System
- Adrenergic Receptor Subtypes & Second Messengers
Receptor G-Protein Second Messenger Primary Tissue Distribution Key Physiological Effects
α 1 \alpha_1 α 1 G q G_q G q ↑ I P 3 , D A G , C a 2 + \uparrow IP_3, DAG, Ca^{2+} ↑ I P 3 , D A G , C a 2 + Vascular smooth muscle, pupillary dilator, bladder sphincter Arterial/venous vasoconstriction ( ↑ S V R , ↑ B P \uparrow SVR, \uparrow BP ↑ S V R , ↑ BP ), mydriasis , internal urethral sphincter contraction
α 2 \alpha_2 α 2 G i G_i G i ↓ cAMP \downarrow \text{cAMP} ↓ cAMP Presynaptic sympathetic terminals, pancreatic β \beta β -cells Inhibits norepinephrine release (central sympatholysis), decreases insulin secretion, decreases aqueous humor production
β 1 \beta_1 β 1 G s G_s G s ↑ cAMP , P K A \uparrow \text{cAMP}, PKA ↑ cAMP , P K A Myocardium, SA node, AV node, juxtaglomerular cells ↑ \uparrow ↑ Heart rate (chronotropy), ↑ \uparrow ↑ contractility (inotropy), ↑ \uparrow ↑ AV conduction (dromotropy), ↑ \uparrow ↑ renin secretion
β 2 \beta_2 β 2 G s G_s G s ↑ cAMP , P K A \uparrow \text{cAMP}, PKA ↑ cAMP , P K A Bronchial smooth muscle, vascular smooth muscle, skeletal muscle Bronchodilation , skeletal muscle arteriolar vasodilation, uterine relaxation (tocolysis) , ↑ N a + / K + \uparrow Na^+/K^+ ↑ N a + / K + ATPase activity (causes hypokalemia), ↑ \uparrow ↑ glycogenolysis
β 3 \beta_3 β 3 G s G_s G s ↑ cAMP \uparrow \text{cAMP} ↑ cAMP Adipose tissue, detrusor bladder muscle Lipolysis, detrusor muscle relaxation (Mirabegron for overactive bladder)
Sympathomimetic Agonists
Epinephrine : Potent endogenous agonist across all alpha and beta receptors. At low therapeutic doses ( 0.01 – 0.05 mcg/kg/min 0.01\text{--}0.05\text{ mcg/kg/min} 0.01 – 0.05 mcg/kg/min ), β 1 \beta_1 β 1 and β 2 \beta_2 β 2 effects predominate (bronchodilation, ↑ \uparrow ↑ cardiac output, decreased peripheral resistance). At high doses ( > 0.1 mcg/kg/min > 0.1\text{ mcg/kg/min} > 0.1 mcg/kg/min ), α 1 \alpha_1 α 1 vasoconstrictor effects override β 2 \beta_2 β 2 , driving marked systemic hypertension. Drug of choice for Anaphylaxis ( 0.3 – 0.5 mg 0.3\text{--}0.5\text{ mg} 0.3 – 0.5 mg IM 1 : 1 , 000 1:1,000 1 : 1 , 000 in anterolateral thigh) and cardiac arrest.
Norepinephrine : Potent α 1 \alpha_1 α 1 and α 2 \alpha_2 α 2 agonist with moderate β 1 \beta_1 β 1 activity and negligible β 2 \beta_2 β 2 effect. Produces intense systemic vasoconstriction with elevated mean arterial pressure. First-line vasopressor for Septic Shock .
Dopamine : Dose-dependent receptor activation:
Low dose ( 1 – 2 mcg/kg/min 1\text{--}2\text{ mcg/kg/min} 1 – 2 mcg/kg/min ): D 1 D_1 D 1 receptors → \to → renal and mesenteric vasodilation.
Intermediate dose ( 2 – 10 mcg/kg/min 2\text{--}10\text{ mcg/kg/min} 2 – 10 mcg/kg/min ): β 1 \beta_1 β 1 receptors → \to → positive inotropy.
High dose ( > 10 mcg/kg/min > 10\text{ mcg/kg/min} > 10 mcg/kg/min ): α 1 \alpha_1 α 1 receptors → \to → generalized vasoconstriction.
Dobutamine : Predominantly β 1 > β 2 \beta_1 > \beta_2 β 1 > β 2 selective inotrope; increases cardiac output with minimal change in heart rate and mild vasodilation. Drug of choice for acute cardiogenic shock without profound hypotension.
Phenylephrine : Pure selective α 1 \alpha_1 α 1 agonist; induces intense vasoconstriction, increasing systolic and diastolic blood pressure with compensatory reflex vagal bradycardia.
Clonidine & Methyldopa : Centrally acting selective α 2 \alpha_2 α 2 agonists. Stimulate presynaptic α 2 \alpha_2 α 2 receptors in the medullary vasomotor center, suppressing sympathetic outflow, reducing blood pressure and heart rate. Abrupt cessation of clonidine triggers severe rebound hypertensive crisis due to sympathetic surge. Methyldopa is a classic first-line agent for chronic hypertension in pregnancy; major adverse effect is a Coombs-positive autoimmune hemolytic anemia .
Sympatholytic Antagonists: Alpha- and Beta-Blockers
Alpha-Adrenergic Blockers :
Phenoxybenzamine : Non-selective, irreversible covalent blocker of α 1 \alpha_1 α 1 and α 2 \alpha_2 α 2 receptors. Used preoperatively in pheochromocytoma to prevent catastrophic intraoperative hypertensive crises during surgical tumor manipulation.
Phentolamine : Non-selective, reversible alpha-blocker. Used for acute hypertensive crises associated with pheochromocytoma manipulation or MAO inhibitor-tyramine food interactions, and for local extravasation of norepinephrine infusions.
Prazosin, Doxazosin, Terazosin : Selective α 1 \alpha_1 α 1 antagonists; relax vascular arteriolar and venous smooth muscle and prostatic smooth muscle. Used for comorbid hypertension and Benign Prostatic Hyperplasia (BPH). Notable adverse effect: First-dose syncope and marked orthostatic hypotension (must be taken at bedtime).
Tamsulosin & Silodosin : Selective α 1 A \alpha_{1A} α 1 A receptor blockers localized to the prostate and bladder neck; relieve urinary obstruction in BPH with minimal vascular hypotension. Can cause Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery.
Beta-Adrenergic Blockers :
Cardioselective ( β 1 \beta_1 β 1 -Selective; "A to M") : Metoprolol, Atenolol, Bisoprolol, Esmolol, Nebivolol . Safer in patients with concomitant mild asthma, COPD, or peripheral artery disease. Esmolol is an ultra-short-acting agent ( t 1 / 2 ≈ 9 minutes t_{1/2} \approx 9\text{ minutes} t 1/2 ≈ 9 minutes ) metabolized by red blood cell esterases, ideal for acute aortic dissection and intraoperative arrhythmias. Nebivolol also stimulates endothelial nitric oxide release, providing direct vasodilatory action.
Non-Selective ( β 1 + β 2 \beta_1 + \beta_2 β 1 + β 2 ; "N to Z") : Propranolol, Timolol, Nadolol . Strictly contraindicated in patients with active asthma or severe COPD due to life-threatening bronchospasm. Non-selective beta-blockers mask early warning signs of hypoglycemia (tachycardia, tremor, anxiety) in diabetic patients, though diaphoresis (sweating) is spared because it is mediated by cholinergic muscarinic innervation of eccrine glands.
Combined α 1 \alpha_1 α 1 and Beta-Blockers : Carvedilol, Labetalol . Labetalol is first-line for hypertensive emergencies, acute aortic dissection, and preeclampsia/severe gestational hypertension. Carvedilol reduces all-cause mortality in chronic heart failure.
Intrinsic Sympathomimetic Activity (ISA / Partial Agonists) : Pindolol, Acebutolol . Act as weak partial agonists, causing less resting bradycardia; they are avoided after myocardial infarction because they lack the mortality benefit of other beta-blockers.
Adverse drug reactions and monitoring
Type A (augmented): predictable from the drug's pharmacology and dose-related. Examples are bleeding with warfarin and hypoglycemia with insulin. These are the most common.
Type B (bizarre): idiosyncratic or immunologic and not dose-related. Examples are anaphylaxis to penicillin, SJS with carbamazepine, and agranulocytosis with thionamides or clozapine.
Other types:
- chronic (adrenal suppression with steroids);
- delayed (teratogenicity, carcinogenicity);
- end-of-use (rebound hypertension after stopping clonidine, beta-blocker withdrawal);
failure of therapy (interactions that lower efficacy).
Drug-food and drug-laboratory interactions:
- grapefruit juice raises levels of some statins and calcium channel blockers;
- tyramine-rich foods with MAO inhibitors cause hypertensive crisis;
- vitamin K-rich foods reduce warfarin's effect;
- dairy, antacids and iron chelate tetracyclines and fluoroquinolones;
biotin interferes with some immunoassays (thyroid tests, troponin).
Pharmacovigilance: suspected adverse reactions are reported to the FDA Philippines .
Monitoring plans combine:
therapeutic drug levels for narrow-therapeutic-index drugs;
safety laboratory tests , such as liver enzymes with statins and INH, creatinine and potassium with ACE inhibitors, CBC with clozapine and thionamides, and TSH with amiodarone and lithium;
clinical endpoints : BP, glucose, symptoms.
Special populations:
- older adults : lower renal function, more sensitivity, polypharmacy;
- children : weight-based dosing;
- pregnancy and lactation : weigh fetal risk against maternal benefit;
renal and hepatic impairment : adjust doses (for example, by creatinine clearance).
Philippine Prescribing Regulations & Medical Jurisprudence
Prescription writing in the Republic of the Philippines is governed by strict statutory frameworks designed to ensure generic accessibility and prevent the diversion of dangerous drugs.
The Generics Act of 1988 (Republic Act No. 6675)
Republic Act No. 6675 mandates all licensed medical practitioners to write prescriptions using the generic name of the drug. The statutory requirements are established in administrative regulations (DOH Administrative Order No. 62 s. 1989):
The generic name must be written in full and legibly.
The generic name must always precede the brand name.
If a brand name is written, it must be enclosed in parentheses immediately following the generic name (e.g., Amoxicillin 500 mg capsule (Amoxil) ).
Prescription Classification Definition under DOH AO 62 (s. 1989) Pharmacist's Action
Erroneous Prescription (1) Brand name precedes the generic name; (2) the generic name is the one in parentheses; (3) the brand name is not in parentheses Filled , then kept and reported to the nearest DOH office
Violative Prescription (1) Generic name not written ; (2) generic name illegible while a legible brand name is written; (3) brand name with instructions such as "No Substitution" that obstruct generic dispensing Not filled ; kept and reported to the DOH; the pharmacist advises the prescriber and/or tells the patient to get a proper prescription
Impossible Prescription (1) Only the generic name is written but it is illegible; (2) the generic name does not correspond to the brand name; (3) both names are illegible; (4) the drug is not registered with the FDA Not filled ; the pharmacist advises the prescriber and/or tells the patient to get a proper prescription, and reports it
A later amendment (AO 90, s. 1990) allowed more than one drug product on one prescription form.
The Comprehensive Dangerous Drugs Act of 2002 (Republic Act No. 9165)
RA 9165 and Dangerous Drugs Board Regulation No. 1 (s. 2014) govern prescriptions for dangerous drugs such as morphine, fentanyl, oxycodone, pethidine and methylphenidate:
Prescriber: a physician, dentist or veterinarian with a valid PDEA S-2 license .
Form: the DOH Special Prescription Form for dangerous drugs (the "yellow prescription"), unless the drug is exempted; certain oral Schedule 4 and 5 preparations (and buprenorphine patches) are prescribed on an ordinary prescription in triplicate bearing the S-2 number.
One dangerous drug per prescription , signed and dated on the day of issue.
Triplicate copies: the original is surrendered to the dispensing pharmacy, the duplicate is the patient's copy , and the triplicate is retained by the prescriber.
Contents: the prescriber's name, address, contact details, S-2 license number and validity, and PTR; the patient's name, age and address; the date; the generic and brand name, strength and form; the total quantity in words and figures; and directions.
Quantity: up to a 30-day supply per prescription. In extraordinary circumstances the prescriber may issue multi-month prescriptions (each for no more than 30 days, numbered "1 of 3", etc.). Up to 60 days of certain Schedule 4 drugs may be prescribed for epilepsy and dystonia.
Dispensing: the pharmacist stamps "USED IN FULL" or records partial dispensing, and must not dispense a prescription that is forged, altered, incomplete, or presented more than 60 days after issue.
Special forms are non-transferable and used consecutively. Unused forms are surrendered when the prescriber stops practice or the S-2 license lapses.
A temporary DDB regulation (BR 10, s. 2025) allowed ordinary triplicate prescriptions in place of yellow forms until June 30, 2026, for continuity of care during public health emergencies.